Fig. 7.
Fig. 7. Recipients of unmodified stem cell products from G-CSF-treated donors receive more DC2 than recipients of unmodified marrow. / Sample aliquots were obtained from either marrow (n = 15) or peripheral blood stem cells (n = 7) intended for allogeneic transplantation. After lysis of erythrocytes, cells were labeled with FITC-conjugated antibodies to lineage markers CD3, CD14, CD16, CD19, CD20, CD34, CD56, IgM, anti-HLA-DR PerCP, and either anti-- CD11c or anti-IL-3Rα PE for the identification of DC1 and DC2, respectively. Absolute DC counts were determined as described in “Materials and methods.” Each symbol represents a single sample. Median values are represented by horizontal lines in each series. P values were determined using t tests for independent samples.

Recipients of unmodified stem cell products from G-CSF-treated donors receive more DC2 than recipients of unmodified marrow.

Sample aliquots were obtained from either marrow (n = 15) or peripheral blood stem cells (n = 7) intended for allogeneic transplantation. After lysis of erythrocytes, cells were labeled with FITC-conjugated antibodies to lineage markers CD3, CD14, CD16, CD19, CD20, CD34, CD56, IgM, anti-HLA-DR PerCP, and either anti-- CD11c or anti-IL-3Rα PE for the identification of DC1 and DC2, respectively. Absolute DC counts were determined as described in “Materials and methods.” Each symbol represents a single sample. Median values are represented by horizontal lines in each series. P values were determined using t tests for independent samples.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal